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Abstract
Objectives: To characterise spontaneous adverse drug reactions (ADRs) reported in the former German 
Democratic Republic (GDR) and to identify ADRs related to quality problems with pharmaceuticals. 
 Material and methods: In 1964 a spontaneous ADR reporting system was established in the GDR with the 
purpose to collect information about possible toxic and damaging ADRs from medicine use. The spontaneous 
reporting system was also seen as an important tool for securing the quality of the pharmaceutical production. Data 
on ADRs occurring in the GDR were located in the national German archive, Bundesarchive in Berlin. Only ADR 
reports submitted from 1982 to 1990 were identified. The reports were analysed with respect to type of ADR (System 
Organ Class [SOC]) and substance. 
Results: From 1982 to 1990 a total of 3990 ADR reports covering information about 6706 ADRs were submitted 
to the GDR health authorities. The largest share, 26% of all ADRs referred to the SOC “skin and subcutaneous 
disorders”, followed by the SOCs “general disorders and administration site conditions” (23% of total ADRs) and 
“gastrointestinal disorders” (11% of total ADRs). Two-thirds of all ADRs were related to the therapeutic groups: “anti-
infectives for socs use” (ATC group J) and “blood and blood forming organs” (ATC group B). Approximately 85% 
of ADRs from ATC group B was reported for dextran 40, the majority of these ADRs of the general type, followed 
by skin ADRs and ADRs concerning respiratory disorders. Additionally a high number of circulatory collapse/shock 
were reported for dextran 40. The increased level of ADR reporting was related to an abnormal distribution of low 
and high molecules of dextran 40 occurring due to production problems. Fifteen percent of ADRs were reported for 
radiographic contrast media; the majority for the substance amidotrizoate, and more than one half of these were of 
the type skin and respiratory disorders. 
 Conclusion: In the GDR during the 1980s, the spontaneous ADR reporting system managed to detect serious 
pharmaceutical quality problems in dextran products. The products of lower quality could not be replaced easily due 
to lack of safer national alternatives as well as lack of foreign currency necessary to import of purer products from 
Western countries.
Keywords: Pharmacovigilance; Spontaneous Reporting Systems; 
German Democratic Republic; Pharmaceutical Quality; Dextran; 
Contrast Media 
Introduction
The German Democratic Republic (GDR) (1949 to 1990) was 
known for its well developed pharmaceutical industry organized in 
state-owned companies that produced several pharmaceuticals, both 
original as well as generic products [1]. The generics were copies of 
pharmaceuticals already marketed 3 to 5 years previously in western 
countries and had to follow the international patent law [2]. Efficacy 
and safety assessments of generics were based on existing international 
data [1-2]. From 1951 to 1989 a total of 48 original products were 
developed by the GDR pharmaceutical industry, e.g. the anabolic 
steroid chlordehydromethyltestosteron (Oral-Turinabol®) and the 
beta-blocker talinolol (Cordanum®) [1]. Despite the difficult financial 
situation after World War II innovative product development 
increased in the 1960s and 1970s resulting in an expansion of the 
GDR pharmaceutical industry [3]. However over the time, the 
temporary lack of chemicals, packing material, limited capacities for 
pharmacological and toxicological testing and production equipment 
restricted the further expansion [4]. Good Manufacturing Practice 
(GMP) and Good Laboraty Practice (GLP) based on the World Health 
Organization (WHO) standards were implemented in the GDR 
[5]. In the 1960s systems for the reporting of adverse drug reactions 
(ADRs) were established at national level, and internationally by the 
WHO, to collect information about ADRs following medicine use, 
particularly with regard to rare and serious reactions [6]. To comply 
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with the WHO recommendations in the GDR a similar ADR reporting 
system was introduced in 1964 like in other countries, with the purpose 
to collect information about possible toxic and harmful ADRs from 
medicine use [5]. In addition in the GDR the spontaneous reporting 
system was also viewed as an important tool for securing the quality 
of the pharmaceutical production [7]. Internationally, only limited 
information about ADRs reported in the GDR as well as and other 
Eastern European countries has been available [8]. The fall of the Berlin 
wall has allowed access to reports on ADRs, that previous was treated 
as state secrets and with access to only a few people. The objective of 
this study was to characterise spontaneous ADRs reported in the GDR 
with respect to type of reported ADRs and suspected substances, and to 
identify ADRs related to quality problems with pharmaceuticals. 
Setting 
The pharmaceutical industry and medical supply system in 
the GDR 
The GDR pharmaceutical industry was organized through a 
cooperation of all major pharmaceutical companies named GERMED 
with its main center at the Arzneimittelwerk (AWD) Dresden 
[3]. GERMED constituted 12 pharmaceutical factories and within 
GERMED specialization concerning therapeutic areas was supported. 
Berlin Chemie maintained the insuline production and Jenapharm 
the production of hormones and antibiotics [3]. Another form of 
specialization referred to the way of administration or dosage form of 
the medication, i.e. the production of eye drops and inhalation sprays 
were maintained by Ankerwerk Rudolstadt, suppositories and ovules by 
Pharmamed Naumburg and liquids by the company Ysat Wernigerode 
[3]. In the GDR prescription medicines were dispensed to patients 
free of charge and over-the- counter medicines were sold at low prices 
through state-owned pharmacies [9]. Approximately 75 % of licensed 
medications were prescription only [9]. In 1949 approximately 5000 
medications was produced in the GDR, but this number was reduced 
much heavily to around 1700 in 1951, as only medications which were 
considered rational with respect to efficacy and safety were allowed 
to remain on the market [9]. The licensed medications were listed in 
the national medication compendium, the “Arznemittelverzeichnis”, 
which was issued annually [9]. Table 1 displays the distribution of the 
number of licensed pharmaceutical products in the GDR distributed 
by different manufacturers and listed in the “Arzneimittelverzeichnis” 
[9]. For a small country like the GDR, which did not have the economic 
power to have a pharmaceutical industry large enough to cover the need 
for all needed medical supplies within the GDR a considerable number 
of pharmaceuticals was also imported from other Eastern European 
countries as well as non-socialist countries [4]. Over the years, 
approximately 1750 medications (range 1440 to 2043) were licensed 
for use in the GDR. Of these medications around 1000 (range 1343 to 
1900) were produced by the GDR pharmaceutical industry and some of 
these even produced by local pharmacies called “Standardrezepturen” 
[4]. Another 250 pharmaceutical products (range 108 to 244) were 
imported from other socialist countries and about 200 (range 17 to 
399) from non-socialist countries [4]. 
GDR national ADR reporting system 
In 1964 a national ADR surveillance program was established by law 
by the GDR’s Ministry of Health and in 1969 an official ADR reporting 
form was launched together with information about the importance 
of reporting ADRs [7, 9-11]. Initially physicians and pharmacists were 
requested to report ADRs however reporting was voluntary. In 1981, 
in order to increase the number of submitted ADR reports, mandatory 
reporting was introduced for physicians [8]. To submit an ADR report 
the following information was required: age and gender of the patient; 
severity and characteristics of the ADR(s), suspected medicine and 
also concomitant medicines, indication for use, dosage, treatment 
period, date of onset of the ADR, causality assessment and other 
Year GDR productions Pharmaceuticals imported from Eastern Europe 
Pharmaceuticals  imported from 
Western countries  Total 
1951 1900 NR NR 1900
1954 1511 NR NR 1511
1957 1685 NR NR 1685
1959 1680 NR NR 1680
1961 1440 NR NR 1440
1962 NA NA NA NA
1969 NA NA NA NA
1970 NA NA NA NA
1971 1397 108 17 1522
1972 1397 108 17 1522
1973 NA NA NA NA
1974 NA NA NA NA
1975 NA NA NA NA
1976 1348 148 29 1525
1977 NA NA NA NA
1979 NA NA NA NA
1980 1343 141 26 1510
1981 1367 204 249 1820
1982 NA NA NA NA
1983 NA NA NA NA
1984 NA NA NA NA
1988 1392 244 234 1870
1990 1412 232 399 2043
NR: not reported; NA: data not available
Table 1: Licensed pharmaceutical products (number) in the German Democratic Republic distributed by type of producer, listed in the national medicines compendium.
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relevant information such as laboratory data if available [8]. All reports 
were made on paper as at that time no electronic reporting system or 
reporting by the telephone was established. The spontaneous reporting 
system was managed by the “Institut für Arzneimittelwesen der DDR” 
(IFAR) [8]. All suspected cases, including unknown ADRs, serious 
ADRs, ADRs due to interactions with other drugs, and ADRs resulting 
in endangering of life or resulting in death were to be reported and 
centrally documented [11]. Formal assessments of ADR reports were 
initiated in 1977. Scientific staff working at IFAR evaluated the reports 
and if the reported ADRs were suspected to be caused by defects in 
quality of the medicines, further investigations were initiated. All 
other cases were examined by the “Problem commission of Clinical 
Pharmacology” located in Dresden [11]. Hence the majority of ADR 
reports were only tracked in special cases, and no general practice 
for analysing these cases existed. Results of the internal analysis 
were usually not published and written feed-back was only provided 
to the reporter and pharmaceutical companies in cases where the 
ADRs were caused by a quality defect of the administered drug [11]. 
This system was in place until the German Reunification in October 
1990. The GDR joined the international WHO collaboration on drug 
safety in 1983 and from the summer of 1985 until 1990 selected ADR 
cases were forwarded to the WHO database. The intention of the 
selection process was that only new ADRs should be reported to avoid 
“unnecessary”overreporting. The characteristics of these ADR cases 
have been reported elsewhere [8]. Table 2 lists selected cases of serious 
ADR cases leading to withdrawal of the products from the market in 
the GDR. Decisions of withdrawal were made on the basis of both own 
and international observations on serious ADRs. 
Material and Methods
Data on ADRs reported in the GDR were provided from several 
sources and types of material. Material was searched in the national 
German archives, Bundesarchive, in Berlin as well as databases and 
websites. All relevant identified material was retrieved. The analysed 
material covered the period from 1964 to 1990 and derived from 
two main sources: a) ADR data reported in the German Democratic 
Republic from 1982 to 1990 and b) reports and correspondences 
between GDR health authorities and pharmaceutical companies 
and other relevant stakeholders. Information about ADRs occurring 
in the GDR and reported to IFAR from 1982 to 1990 was retrieved. 
Documents from 1969 to 1981 could not be located in the archive 
although former employees of the IFAR had confirmed that all files 
were stored in the Bundesarchive after the reunification (personal 
communication). Furthermore, we were not able to get copies of the 
original ADR reports, but were allowed access to extracts of information 
which had been manually entered into protocols by IFAR employees at 
the time of reporting. In these protocols information about suspected 
medications, batch number, reported ADRs, deaths and whether the 
reports had been forwarded to the Prague Pharmacovigilance centre 
and/or the WHO ADR database VigiBase was present. For some of 
the ADR reports information about evaluation patterns as well as 
established quality problems for the reported batches was found, 
however, this information was not systematically documented, and 
therefore could not be included in this study. 
Analysis
Data were extracted from the ADR register and protocols into 
Excel files using the following categories: ATC (anatomical therapeutic 
chemical) [12] code of medications, trademark and active substance 
of the medicines, ADRs coded according to MedDRA terminology 
at System Organ Class (SOC) level [13]. The process was very time 
consuming due to the large amount of data which were written in 
German language and had to be translated into English. In order 
to present the large amount of data in a comprehensive way, the 
medicines for which the ADRs are reported are presented at ATC level 
1. Information about seriousness of reported ADRs as well as age and 
sex of patients was not available in the ADR protocols of IFAR. 
Results
From 1982 to 1990 a total of 3990 ADR reports (range 233 to 
537 per year) covering information about 6706 ADRs (range 373 to 
926) were submitted to the GDR health authorities. Approximately 
60% of ADR reports concerned inpatients and 40 % outpatients. On 
average, 10 fatal ADR cases were reported per year (range 7 to 20). 
Table 3 displays the number of ADRs reported in the GDR from 1982 
to 1990 classified according to the affected system organ class (SOC) 
and the therapeutic groups. The largest share, 26% of all ADRs referred 
to “skin and subcutaneous disorders”, followed by the SOC “general 
disorders and administration site conditions” (23% of total ADRs) and 
“gastrointestinal disorders” (11% of total ADRs). 
*Sub-acute myelo-optico neuropathy
Table 2:  Medications marketed in the German Democratic Republic (GDR) but withdrawn due to negative risk-benefit evaluations by health authorities, selected cases 
1982 to 1990.
Year of 
marketing
Year of 
withdrawal Medication (s) Substance (s) Adverse drug reaction (s) GDR cases (N)
1966 1984
Enteroseptol
Entero-Vioform
Mexaform plus
Clioquinol
Dichlorquinol SMON* syndrome 0
1969 1984
Aminophenazone
Oramon
Pulmophyllin
Aminophenazone Carcinogenic 0
< 1960 1984 PerclusoneWofapyrin
Phenylbutazone 
combinations Bone marrow supression 11
1969 1984 Ketazon Kebuzon Bone marrow suppression 0
1981 1985 Sotropin H Somatrotopin Creutzfeld-Jacob Syndrome 0
1984 1985 Auroplex Lindane CNS reaction 5
1979 1985 Phenoro Canthaxanthin Retina sediments 3
< 1960 1986 Benedorm Pyrithyldion Dependence 1
< 1960 1986 Bromisoval (Alluval) Bromisovalerianyl Dependence 0
< 1960 1988 Phenylbutazone Phenylbutazone Bonemarrow suppression  84 (3 fatal)
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ATC/System 
Organ Class Blood Card. Cong. Ear Eye Gen. Gastr. Hepa Imm. Inf. Inj. Inv. Met. Mus. Nerv. Preg. Psyc. Renal Resp. Repr. Skin Social Surg. Vasc. Total
Alimentary tract & 
metabolism (A)
A01/A02/A03/A04 0 9 0 0 3 11 11 1 1 0 0 2 0 2 16 1 4 0 2 1 11 0 0 0 75
A06/A07/A08/A09 4 3 0 0 0 5 14 4 1 1 0 0 0 0 5 0 0 0 15 0 15 0 0 3 70
A10/A11 1 3 0 0 0 26 5 0 7 1 1 3 3 0 6 0 1 1 0 3 34 0 0 3 98
A12/A14/A16 1 2 0 0 0 2 8 1 0 1 0 0 0 1 2 0 0 0 2 0 3 0 0 2 25
Total A 6 17 0 0 3 44 38 6 9 3 1 5 3 3 29 1 5 1 19 4 63 0 0 8 268
Blood & blood 
forming  organs 
(B)
B01 8 3 0 0 0 44 12 3 3 1 0 6 0 4 7 0 0 0 4 1 25 0 6 9 136
B02 1 4 0 0 0 8 2 0 5 0 0 1 0 0 0 0 0 0 9 0 1 0 0 4 35
B03 1 3 0 0 0 54 28 0 3 4 0 5 0 0 5 0 2 2 9 0 6 0 0 9 131
B05/06 1 108 0 1 9 554 122 0 104 11 2 96 0 14 41 4 9 7 187 0 227 0 2 103 1602
Total B 18 118 0 1 9 660 164 3 115 16 2 108 0 18 53 4 11 9 209 1 259 0 8 125 1904
Cardiovascular 
system (C) 
(C01 1 8 0 0 2 10 15 0 3 0 1 1 0 0 8 0 0 0 5 2 15 0 0 5 76
C02 4 1 0 0 3 8 13 42 3 1 0 1 0 0 8 0 2 3 3 0 11 0 0 0 103
C03/C04/C05 1 8 0 0 2 8 31 0 9 0 0 5 0 3 13 0 0 1 1 0 36 0 0 2 120
C07/C08/C09/C10 0 4 0 1 4 11 13 4 3 1 0 0 0 3 11 0 3 0 3 2 33 0 0 1 97
Total C 6 21 0 1 11 37 72 46 18 2 1 7 0 6 40 0 5 4 12 4 95 0 0 8 396
Dermatologicals 
(D)
D01/D02/D03 1 0 0 0 2 2 5 0 0 1 0 0 0 1 3 0 1 0 0 0 16 0 0 0 32
D04/D05 0 1 0 0 3 3 20 0 0 0 0 1 0 0 3 0 0 0 0 0 7 0 0 0 38
D06/D07 0 0 0 0 0 5 1 0 0 1 0 0 0 3 1 0 0 0 1 0 7 0 0 1 20
D08/D11 0 0 0 0 0 2 0 0 2 0 0 0 0 0 1 0 0 0 0 0 61 0 0 0 66
Total D 1 1 0 0 5 12 26 0 2 2 0 1 0 4 8 0 1 0 1 0 91 0 0 1 156
Sex hormons (G)
G01/G02 0 0 0 0 0 3 2 0 0 0 0 0 0 0 2 0 1 0 1 0 4 0 0 4 17
G03/G04 0 2 0 0 1 29 10 10 1 0 0 1 0 2 4 0 0 0 0 0 20 0 0 7 87
Total G 0 2 0 0 1 32 12 10 1 0 0 1 0 2 6 0 1 0 1 0 24 0 0 11 104
Systemic 
hormonal prep. (H)
H01/H02 0 9 0 0 0 31 9 0 2 1 0 4 0 1 5 0 1 0 16 0 29 0 0 9 117
H03/H04 1 2 0 0 0 3 2 2 0 0 0 0 0 0 1 0 0 0 0 0 9 0 0 1 21
Total H 1 11 0 0 0 34 11 2 2 1 0 4 0 1 6 0 1 0 16 0 38 0 0 10 138
Anti-infectives for 
systemic  use (J)
J01 11 24 1 3 11 158 77 25 53 12 0 10 0 7 38 0 4 1 40 1 334 0 1 26 837
J02/J04/J05/J06 4 1 0 0 0 53 3 1 3 6 0 0 0 5 5 0 0 3 1 0 31 0 0 4 120
J07 15 25 1 3 11 211 80 26 56 18 0 10 0 12 43 0 4 4 41 1 365 0 1 30 957
Total J 30 50 2 6 22 422 160 52 112 36 0 20 0 24 86 0 8 8 82 2 730 0 2 60 1914
Antineoplastic & 
immuno. (L)
L01/L02/L04 3 4 0 0 0 18 4 3 4 4 0 1 0 0 4 0 0 0 5 0 17 0 0 2 69
Total L 3 4 0 0 0 18 4 3 4 4 0 1 0 0 4 0 0 0 5 0 17 0 0 2 69
Musculoskeletal 
system (M)
M01 12 10 0 0 0 40 56 25 4 12 0 5 0 4 15 0 4 2 10 0 64 0 0 16 279
M02/M03/M04 2 8 0 0 1 19 42 0 5 0 6 1 0 3 11 0 3 0 2 0 37 0 0 1 161
Total M 14 18 0 0 1 59 118 25 9 12 6 6 0 7 26 0 7 2 12 0 101 0 0 17 440
Nervous system 
(N)
N01 2 10 0 0 1 45 12 5 13 2 0 10 0 0 35 0 3 0 14 0 37 1 0 19 209
N02 9 16 1 2 1 48 17 4 18 1 1 4 0 2 18 0 3 2 14 0 72 0 0 15 248
N03 2 2 0 1 3 17 20 6 3 0 0 1 0 0 16 0 5 1 1 0 31 0 0 0 109
N04/N05/N06/N07 17 11 0 0 3 34 23 7 2 1 1 4 0 0 25 0 13 1 5 0 13 0 1 12 173
Total 30 39 1 3 8 144 72 22 36 4 2 19 0 2 94 0 24 4 34 0 153 1 1 46 739
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ADRs by therapeutic group
Two-thirds of all ADRs were seen in the therapeutic groups: “anti-
infectives for systemic use” (ATC group J), predominantly antibacterials 
(ATC group J01) and vaccines (ATC group J07) and “blood and blood 
forming organs” (ATC group B). Approximately 15% of ADRs were 
reported for medications from ATC group V (various), particularly 
for contrast media agents (ATC group V08). Within ATC group B 
the majority of ADRs was reported for plasma volume expanders, 
particularly dextrans (N = 773). Table 4 displays the characteristics of 
ADRs reported for dextran containing products marketed in the GDR 
reported from 1982 to 1990. The majority of reports, 83% of total ADRs 
was reported for dextran 40, followed by 11% of ADRs reported for 
dextran 40/mannitol, and 6% of reports were reported for dextran 75. 
For dextran 40, the majority of reported ADRs were of the type “general 
disorders and administration site conditions” (N = 181), i.e. chills and 
temperature changes; followed by ADRs concerning skin reactions 
(N = 108) and ADRs concerning respiratory disorders (N= 101). A 
large number of circulatory collapse/shock (N = 39) and anaphylactic 
reactions (N= 25) was also reported for dextran 40. Table 5 displays 
the characteristics of ADRs for the contrast media agent amidotrizoate 
natrium in the GDR from 1982 to 1990. The majority of ADRs (23% 
of total ADRs) were of the type skin disorders, i.e. urticaria followed 
by gastrointestinal ADRs (vomiting and nausea) (21% of total) and 
respiratory ADRs (11% of total), i.e. difficulty breathing. 
Antiparastic (P)
P01 5 2 0 0 0 3 3 0 0 0 0 0 0 0 2 0 2 1 2 0 3 0 0 1 24
P02 1 0 0 0 0 1 8 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 1 14
P03 1 0 0 0 4 1 3 0 0 0 0 0 0 2 5 0 2 0 1 0 4 0 0 2 25
Total P 7 2 0 0 4 5 14 0 0 0 0 0 0 3 8 0 4 1 3 0 8 0 0 4 63
Respiratory 
system
R01/R02/R03 0 10 0 0 0 34 16 0 2 1 0 4 0 3 9 0 7 0 87 0 38 0 0 19 230
R05/R06 0 4 0 0 11 4 8 0 0 0 0 0 0 0 3 0 5 0 3 0 12 0 0 0 50
Total 0 14 0 0 11 38 24 0 2 1 0 4 0 3 12 0 12 0 90 0 50 0 0 19 280
Sensory organs 
(S)
S01 0 1 0 0 28 2 0 0 1 0 0 1 0 0 0 0 0 0 1 0 17 0 1 2 54
Total S 0 1 0 0 28 2 0 0 1 0 0 1 0 0 0 0 0 0 1 0 17 0 1 2 54
Various (V)
V01/V03/V04 0 10 0 0 3 100 33 1 8 0 1 15 0 0 11 0 0 2 19 0 37 0 0 23 263
V06 0 7 0 0 0 55 5 0 1 5 0 5 0 0 3 0 0 1 11 0 13 0 0 2 108
V08/V09/V10 6 27 0 0 9 77 132 3 43 1 2 29 0 3 39 0 8 2 71 0 165 0 0 61 678
Total V 6 44 0 0 12 232 170 4 52 6 3 49 0 3 53 0 8 5 101 0 215 0 0 86 1049
Others 5 2 0 0 5 18 5 2 12 4 0 2 1 2 2 0 3 1 4 0 109 0 0 4 181
Total 121 300 3 11 108 1525 720 171 323 85 12 179 4 75 374 5 82 30 489 11 1755 1 12 317 6706
Abbreviations and definitions used in table 3 
System organ class
Blood: Blood and lymphatic system disorders; Card: Cardiac disorders; Cong: Congenital, familial and genetic disorders; Ear: Ear and labyrinth disorders; Eye: Eye 
disorders; Gen: General disorders and administration site conditions; Gastr: Gastrointestinal disorders; Hepa: Hepatobiliary disorders; Imm: Immune system disorders; 
Inf: Infections and infestations; Inj:Injury, poisoning and procedural complications; Inv: Investigations; Met: Metabolism and nutrition disorders; Mus:Musculoskeletal 
and connective tissue disorders; Nerv: Nervous system disorders; Preg:Pregnancy, puerperium and perinatal conditions; Psyc:Psychiatric disorders; Renal: Renal and 
urinary disorders; Resp:Respiratory, thoracic and mediastinal disorders; Repr:Reproductive system and breast disorder; Skin:Skin and subcutaneous tissue disorders; 
Social:Social circumstances; Surg:Surgical and medical procedures; Vasc:Vascular disorders. 
Anatomical therapeutic chemical code
A01: Stomatological preparations; A02: Medicines used for acid related disorders; A03: Medicines used for functional gastrointestinal disorders; A04: Antimetics and 
antinausants; A06: Laxatives; A07: Antidiarrheals; A08: Antiobesity preparations; A09: Digestives; A10: Medicines used in Diabetes; A11: Vitamins; A12: Mineral 
supplements; A14: Anabolic agents for systemic use; A16: Other alimentary tract and metabolism products. 
B01: Antithrombotic agents; B02: Antihemorrhagics; B03: Antianemic preparations; B05: Blood substitutes and perfusion solutions; B06: Other haematological agents; C01: 
Cardiac therapy; C02: Antihypertensives; C03: Diuretics; C04: Peripheral vasodilators; C05: Vasoprotectives; C07: Beta blocking agents; C08: Calcium channel blockers; 
C09: Agents acting on the renin-angiotensin system; C10: Lipid modifying agents. 
D01: Antifungals for dermatological use; D02: Emollients and protectives; D03: Preparation for treatment of wounds and ulcers; D04: Antipruritics; D05: Antipsoriatics; 
D06: Antibiotics and Chemotherapeutics for dermatological use; D07: Corticosteroids; D08: Antiseptics and desinfectants; D11: Other dermatological preparations; G01: 
Gynaecological anti-infective and antiseptics; G02: Other gynaecological; G03: Sex hormones and modulators of the genital system; G04: Urologicals; H01: Pituitary and 
hypothalamic hormones and analogues; H02: Corticosteroids for systemic use; H03: Thyroid therapy; H04: Pancreatic hormones; J01: Antibacterials for systemic use; 
J02: Antimycotics for systemic use; J04: Antimycobacterials; J05: Antivirals for systemic use; J06: Immune sera and immunoglobulins, J07: Vaccines; L01: Antineoplastic 
agents; L02: Endocrine therapy; L04: Immunosuppressants; M01: Antiinflammatory and antirheumatic products; M02: Topical products for joint and muscular pain; 
M03: Muscle relaxants; M04: Antigout preparations; N01: Anaesthetics; N02: Analgesics; N03: Antiepileptics; N04: Anti-Parkinson medications; N05: Psycholeptics; 
N06: Psychoanaleptics; N07: Other nervous system medications; P01: Antiprotozoals; P02: Anthelmintics; P03: Ectoparasiticides; R01: Nasal preparations; R02: Throat 
preparations; R03: Medicines used for obstructive airway diseases; R05: Cough and cold preparations, R06: Antihistamines for systemic use; S01: Ophthalmologicals; V01: 
Allergens; V03: Other therapeutic products; V04: Diagnostic agents; V06: General nutritients, V08: Contrast media; V09: Diagnostic radiopharmaceuticals; V10: Surgical 
dressings.
Table 3: Adverse drug reactions (N) reported in the German Democratic Republic distributed by therapeutic group (Anatomical Therapeutical Chemical Code [ATC]) and 
type (system organ class) 1982 to 1990.
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System Organ Class Dextran 40 Dextran 40, 100 mannitol Dextran 75
Cardiac disorder Bradycardia (6) Decreased heart Rhythm (1) Atrial fibrillation (1) 
Cardiac disorder (13) Tachycardia (6) Tachycardia (1)
Palpitation (1) Heart race (1) Cardiac disorder (2)
Tachycardia (28)
Total 48 8 4
Eye disorders Conjuctivitis (2) NR NR
Eye burning (2)
 Pupil dilatation (1)   
Total 5 0 0
General disorders Chills (88) Chills (10) Injection site reaction (1)
Dead (1) Temperature increased (6) Chills (2)
Dizziness (1) Pain (1) Temperature increased (3)
Temperature changes (79) Injection site reaction (1)
Head pressure (1) Fever (1)
Pain (5)
Hypotonie (3)
Incompability (1)
 Lack of consciousness (2)   
Total 181 19 6
Gastrointestinal disorders Vomiting (42) Stomach pain (1) Nausea (2)
Stomach pain (2) Nausea (3) Vomiting (1)
Nausea (29) Vomiting (2)
Mouth blister (2)
Hyperstomie (1)
 Diarrhea (4)   
Total 80 6 3
Infections and infestations Flu symptoms (1) NR Pyrogen reaction (1)
 Pyrogen reaction (2)   
Total 3 0 1
Investigations Blood pressure increased (10) Increased pulse (1) Decreased blood pressure (1)
 Pulse changes (3) Blood pressure changes (6) Hypertension (1)
Total 13 7 2
Immune system disorders Anaphylactic reaction/shock (25) Anaphylactic reaction/shock (4) Anaphylactic reaction/shock (11)
Total 25 4 11
Musculoskeletal disorders Muscle pain (24) Back pain (1)  NR
Total 24 1 0
Nervous system disorders Parasthesies (2) Headache (3) Convulsions (1)
Headache (4) Restlessness (1)
Vertigo (1) Uterus contraction (1)
Restlessness (2)
Tingling (2)
 Trembling (1)   
Total 12 5 1
Psychiatric disorders Psychiatric disorder (2) Anxiety (1) Anxiety (1)
Total 2 1 1
Renal and urinary disorders Kidney pain (3) Kidney pain (2)  NR
Total 3 2 0
Respiratory disorders Bronchospasm (74) Lung oedema (2) Difficulty breathing (11)
Cough (3) Difficulty breathing (8)
Cyanosis (17) Cyanosis (2)
Lung oedema (7)
Total 101 12 1
Skin and subcutaneous disorders Urticaria (22) Skin redness (3) Erythema (1)
Rash (2) Urticaria (1) Hot flashes (1)
Pruritus (26) Exanthem (5) Lip oedema (1)
Swelling (3) Hot flashes (1) Rash (3)
Erythem (5) Oedema (3)
Oedema (10)
Blister (8)
Hot flashes (1)
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Discussion
This is the first study which retrospectively has evaluated 
spontaneous ADR reports submitted to the national health authorities 
in the GDR from 1982 to 1990. The GDR spontaneous reporting system 
was well functioning and able to detect production problems in the 
pharmaceutical industry. Analysis showed that the majority of ADR 
reports were found related to dextran 40 products as well as contrast 
media agents. As only limited information in the archives about age 
and gender of the patients affected by the reported cases as well as 
seriousness of reported ADRs was available we focus on the following 
aspects of ADR reporting: 
Number of reported ADRs 
The reported ADRs corresponds to an annual reporting rate of 27 
reports/million inhabitants/year which is low compared to the number 
of licensed medicines in the GDR and the size of the population. In 
the same period the reporting rate in West Germany was 89 reports/
million inhabitants/year [11]. Within the Comecon countries 
reporting rates varied widely, from 7 reports/million inhabitant/
year in the Soviet Union to 243 reports/million inhabitants/year in 
Czechoslovakia [11]. Spontaneous reporting systems are known to 
be biased by underreporting [14]. In the GDR information about 
medications, both efficacy and safety topics were published in the 
medical journal “Medicamentum” which was issued monthly by the 
GDR pharmaceutical industry. This practice may have contributed to 
underreporting, because the GDR physicians might have assumed that 
everything of importance was already known. Despite the low number 
of ADR reports, the reported ADRs were in line with ADRs reported in 
other countries with respect to type and suspected medications. 
ADRs reported for dextrans 
This study showed that spontaneous ADR reports had detected 
quality problems in relation to the production of dextran 40 at 
Serumwerk Bernburg. In the 1960s it was known that an abnormal 
distribution of low and high dextran molecules could lead to 
an increased risk of serious ADRs such as shock and vascular 
disturbances when infused in children and pregnant women [15-18], 
and guidelines for handling serious ADRs were published [19]. In the 
1970s the number of reports on ADRs such as anaphylactic shocks, 
bronchospasm, and circulatory collapses/shocks reported for dextran 
40 increased in the GDR. Internationally only few studies analysing 
spontaneous ADRs from use of dextrans has been reported [19-21]. 
In the US 366 reports, 25% of these being serious, was reported for 
dextran 40 and dextran 70 from 1969 to 2004 [20]. The majority of 
serious ADRs were anaphylaxis/anaphylactic events [20]. From 1970 
to 1979 the incidence of severe ADRs per unit administered dextran 
40 in Sweden was 0.013% [21]. We only have few informations about 
the GDR ADR rates, however in 1982 the rate of serious ADRs was 
estimated as being 0.011% increasing to 0.02% in 1984 [22]. The 
numerous ADRs lead to considerations whether the figures from GDR 
represented a real increase in reports in the GDR, given that reporting 
Exanthem (26)
 Itching (5)   
Total 108 13 6
Vascular disorders Circulatory collaps/schock (39) Circulatory collaps/schock (4) NR
Total 39 4 0
Total ADRs (N) 645 82 46
Table 4: Characteristics of adverse drug reactions (N) reported for dextrans containing products reported from 1982 to 1990 in the German Democratic Republic (numbers 
in brackets).
rates had increased temporarily due to previous under-reporting, or if 
there were specific problems with GDR products of dextrans [22]. An 
inspection carried out by IFAR at Serumwerk Bernburg in 1978 showed 
that only 50 % of dextran 40 and dextran 75 molecules were within 
the optimal range of molecule size, and high share of high number 
dextran molecules was suspected to have caused the reported ADRs 
[22]. In order to curb the increasing number of serious ADRs a new 
production method, partial fractionation, was introduced for dextran 
75 in 1980, and the number of ADR reports declined [22]. In 1984 
it was decided to introduce a new production technique for dextran 
40, continuous fermentation, which was also used internationally, 
however due to lacking of financial resources and production orders 
at Serumwerk Bernburg the technique, could not be implemented until 
1990 [23]. In 1985 import of dextran 1 (Promit) from Knoll AG in 
West Germany for restricted use in gynaecology was initiated as it was 
assumed that the injection of dextran 1 before dextran 40 could reduce 
the level of serious ADRs [24]. Due to limited production capacities of 
dextran 40 at Serumwerk Bernburg an additional import of dextran 
40 from Sweden was necessary, however this dextran was reserved for 
use outside the health care sector, and due to the restricted availability 
of foreign currency the import could not be increased [25]. During 
the whole process IFAR never considered suspending the market 
authorization for dextran 40 as it was not possible for pharmacological 
reasons; gelatine was not a suitable substitute and hydroxyethyl 
starch was not available on the GDR market. Dextrans were used in 
severely ill patients to increase plasma volume and IFAR had to weigh 
between not delivering dextrans to the patients who need it resulting 
in many fatal cases, ore delivering dextrans with pharmaceutical 
quality problems possibly resulting in other cases of ADRs. Other 
examples of quality problems with production of pharmaceuticals in 
the GDR have also been identified [28]. In 1978 sterility problems in 
the production of Mydrum® (tropicamid) eye drops produced at the 
Ankerwerk in Rudolstadt were detected, and the contamination with 
pyrogens was due to problems with the bottle-washing machine. In 
order to solve the contamination problem it was suggested that the 
content of benzalconiumchlorid was increased of factor 20, rather 
than implementing a new machine that was in accordance with GMP 
standards [28]. Ampicillin for injection produced at Pharmachim was 
also contaminated with pyrogens, resulting in many ADR reports of 
skin reactions and increased temperature, however no information was 
found in the archive about which measures were implemented to tackle 
these problems [29].
ADRs reported for contrast media agents
For the contrast media agents’ amidotrizoat and adipiodon a large 
number of allergic ADRs were reported, reactions that were already 
well known at that time and which were communicated to the GDR 
physicians through Medicamentum [26-27]. The large number of 
ADRs was not found to be related to pharmaceutical quality problems, 
and as the number of reports was comparable to international data, no 
further investigations were made. 
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System Organ Class Adverse drug reaction (s) N
Blood and lymphatic system disorders Hemiparesis 6
Thromboembophlebitis 2
Total 8
Cardiac disorder Bradycardia 1
Hypotoni 4
Palpitation 1
Tachycardia 10
Cardiac condition 12
Total 28
Eye disorders Conjunctivitis 1
Eye pressure 6
Ptosis eye lids 1
Pupil dilatation 1
Total 9
Gastrointestinal disorder Diarrhea 6
Mouth swelling 10
Nausea 50
Vomiting 54
Aphonia 1
Lack of efficacy 1
Stomach pain 4
Total 126
General disorders and administration site conditions Dizziness 3
Back pain 1
Chills 12
Dead 1
Feeling uncomfortable 1
Injection site reaction 14
Aplasia 2
Loss of consciouness 6
Temperature changes 16
Total 56
Hepatobiliary disorders Icterus 1
Increase in transaminases 1
Liver damage 1
3
Immune system disorders Anaphylactic schock/reaction 44
Total 44
Infection and infestations Pyrogen reaction 1
Total 1
Injury, poisoning and procedural complications Drug intolerance 2
Total 2
Investigations Hypotoni 1
Disturbance of heart rhytm 1
Changes in blood pressure 17
Pulse disturbances 6
Total 25
Musculoskeletal and connective tissue disorders Muscle tremor 3
Total 3
Nervous system disorders Convulsions 8
Headache 2
Hemiparesis 1
Parasthesia 8
Partial half-page syndrom 1
Restlessness 2
Somnolence 4
Tremble 1
Vertigo 6
Total 33
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Psychiatric disorder Apati 1
Amnesia 1
Anxiety 4
Total 6
Renal and urinary disorders Kidney pain 1
Oliguria 1
Total 2
Respiratory, thoracic and mediastinal disorders Cyanosis 8
Difficulty breathing 51
Lung oedema 7
Total 66
Skin and subcutaneous disorders Blister 23
Erythema 5
Exanthem 15
Itching 2
Oedema 33
Skin redness 17
Urticaria 44
Total 139
Vascular disorders Circulatory collaps/schock 42
Cerebral ischamie 1
Total 43
Total ADRs reported  for amiotrizoat 594
Table 5: Characteristics of adverse drug reactions reported for amiotrizoat used as contrast media (ATC group V08AA01) in the German Democratic Republic, 1982 to 
1990.
Strength and weaknesses of this study 
The strength of this study is that it is the first which systematically 
has collected information about ADRs reported in the GDR. The 
included material comprised ADR reports collected over many years 
which varies in quality and length. The present work was based on 
documentary textual sources located in archives and elsewhere in Berlin 
and represents the authors’ interpretations of the analyzed documents. 
The analysed material does not allow us to conclude if the GDR 
pharmaceutical industry in general was suffering from major problems 
with maintaining the pharmaceutical quality or if the pharmaceuticals 
were of lower quality than those produced in Western countries. In the 
dextran case correspondences between IFAR and Serumwerk Bernburg 
indicated that a high number of ADRs was reported in the GDR due 
to quality problems, but due to continuous lack of financial resources 
and equipment it was often not possible to improve the pharmaceutical 
quality sufficiently [30]. 
Conclusion 
This study showed that the GDR spontaneous reporting systems 
were able to detect, in addition to its original purpose, pharmaceutical 
quality problems. This was further investigated for the production of 
dextrans. However, due to the lack of safer alternatives and foreign 
currency necessary to import purer products from Western countries, 
the products of lower quality could not be replaced easily. 
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